|

Pacritinib Clinical Trials

11 actively recruiting trials across 8 locations

No change since August 2026

Also known as: 937272-79-2, Oral JAK2 Inhibitor SB1518, Pacritinib Citrate, SB 1518, SB-1518 +3 more

Pipeline

Phase 1: 2Phase 2: 7Phase 1/2: 2

Top Sponsors

  • University of Washington2
  • University of Michigan Rogel Cancer Center1
  • Theradex1
  • Shayna Sarosiek, MD1
  • National Cancer Institute (NCI)1

Indications

  • Cancer11
  • Chronic Myelomonocytic Leukemia2
  • Primary Myelofibrosis2
  • Polycythemia Vera2
  • T-Cell Neoplasm1

Duarte, California2 trials

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

City of Hope

Phase 2

Seattle, Washington2 trials

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Other1 trial

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Phase 2

Tampa, Florida1 trial

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Moffitt Cancer Center

Phase 2

Bethesda, Maryland1 trial

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

National Institutes of Health Clinical Center

Phase 1/2

Boston, Massachusetts1 trial

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Dana Farber Cancer Institute

Phase 2

New York, New York1 trial

Pacritinib in CMML

The Mount Sinai Hospital

Phase 1/2

Philadelphia, Pennsylvania1 trial

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Fox Chase Cancer Center - Philadelphia

Phase 1

Milwaukee, Wisconsin1 trial

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

Froedtert & the Medical College of Wisconsin

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.